Portugali - portugali - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

abbvie, lda. - levodopa + carbidopa - gel intestinal - 20 mg/ml + 5 mg/ml - carbidopa 5 mg/ml ; levodopa 20 mg/ml - levodopa and decarboxylase inhibitor - Órfão - duração do tratamento: longa duração

Portugali - portugali - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

abbvie, lda. - paricalcitol - cápsula mole - 1 µg - paricalcitol 1 µg - paricalcitol - n/a - duração do tratamento: longa duração

Euroopan unioni - portugali - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - transtornos da enxaqueca - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Euroopan unioni - portugali - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - agentes antineoplásicos - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Euroopan unioni - portugali - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - o lopinavir, ritonavir - infecções por hiv - antivirals for systemic use, protease inhibitors - o kaletra é indicado em combinação com outros medicamentos anti-retrovirais para o tratamento de adultos, adolescentes e crianças infectadas com vírus da imunodeficiência humana (hiv-1), com idade superior a 14 dias. a escolha do kaletra para tratar inibidor da protease experientes hiv-1 em pacientes infectados devem ser individuais de resistência vírica e tratamento histórico dos pacientes.

Euroopan unioni - portugali - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - infecções por hiv - antivirais para uso sistêmico - o ritonavir é indicado em combinação com outros agentes anti-retrovirais para o tratamento de pacientes infectados com hiv-1 (adultos e crianças de dois anos de idade e mais).

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

abbvie farmacÊutica ltda. - ritonavir - antiviroticos (inibe replicacao virotica)

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

abbvie farmacÊutica ltda. -

Euroopan unioni - portugali - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Portugali - portugali - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

abbvie, lda. - cetorolac - colírio, solução - 5 mg/ml - cetorolac, trometamina 0.5 % (w/v) - ketorolac - n/a - duração do tratamento: curta ou média duração